Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...